M. Charafeddine

Real‐world safety and effectiveness of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in hepatitis C virus genotype 1‐ and 4‐infected patients with diverse comorbidities and comedications: A pooled analysis of post‐marketing observational studies from 13 countries

P. Ferenci, D. Back, S. Bourgeois, 2019, Journal of viral hepatitis.

Efficacy and safety results of patients with HCV genotype 2 or 3 infection treated with ombitasvir/paritaprevir/ritonavir and sofosbuvir with or without ribavirin (QUARTZ II‐III)

T. Pilot‐Matias, G. Foster, K. Agarwal, 2018, Journal of viral hepatitis.

Long‐term safety and efficacy results in hepatitis C virus genotype 1‒infected patients receiving ombitasvir/paritaprevir/ritonavir + dasabuvir ± ribavirin in the TOPAZ‐I and TOPAZ‐II trials

R. Marinho, D. Dieterich, Armando Carvalho, 2020, Journal of viral hepatitis.

Ombitasvir/paritaprevir/ritonavir and dasabuvir±ribavirin for chronic HCV infection in US veterans with psychiatric disorders

M. Kozal, M. Charafeddine, D. Cohen, 2019, Journal of medical virology.

Survival and Complications of Beta-Thalassemia in Lebanon

A. Inati, A. Taher, M. Charafeddine, 2008, Acta Haematologica.

Effect of Hepatitis C Treatment with Ombitasvir/Paritaprevir/R + Dasabuvir on Renal, Cardiovascular and Metabolic Extrahepatic Manifestations: A Post-Hoc Analysis of Phase 3 Clinical Trials

M. Charafeddine, D. Cohen, Y. Bao, 2017, Infectious Diseases and Therapy.

Safety and efficacy of ombitasvir/paritaprevir/ritonavir ± dasabuvir and ± ribavirin in adult renal or liver transplant recipients with HCV infection (CORAL-I: cohorts 3–6)

X. Forns, T. Pilot‐Matias, D. Samuel, 2017 .